LJPC · La Jolla Pharmaceutical Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $75.72M | $33.42M | $23.05M | $10.06M | $0 | $616.0K |
| Cost of Revenue | - | $7.82M | $2.39M | $0 | - | - |
| Gross Profit | - | $25.60M | $20.66M | $10.06M | - | - |
| R&D | $5.01M | $23.01M | $85.33M | $117.30M | $84.58M | $62.29M |
| SG&A | $35.39M | $38.43M | $45.13M | $16.70M | $30.85M | $16.70M |
| Total Operating Expenses | $53.89M | $69.26M | $132.85M | $204.11M | $115.43M | $78.99M |
| D&A | $111.0K | $2.19M | $4.55M | $4.41M | $1.27M | $730.0K |
| Operating Income | $21.83M | ($35.84M) | ($109.80M) | ($194.05M) | ($115.43M) | ($78.37M) |
| Interest Expense | - | - | - | $0 | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | $0 |
| Net Income | $19.66M | ($39.42M) | ($116.51M) | ($199.47M) | ($114.80M) | ($78.19M) |
| EPS - Basic | ($1.44) | - | - | - | - | - |
| EPS - Diluted | ($1.44) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $46.67M | $21.22M | $87.82M | $172.60M | $90.92M | $65.73M |
| Accounts Receivable | $8.61M | $5.83M | $2.96M | $1.38M | - | - |
| Inventory | $6.28M | $6.01M | $2.21M | $2.02M | - | - |
| Accounts Payable | $2.28M | $2.76M | $4.18M | $8.57M | $11.48M | $6.65M |
| Current Assets | $67.31M | $36.46M | $97.46M | $181.12M | $94.06M | $67.43M |
| Total Assets | $101.23M | $72.24M | $132.25M | $204.29M | $119.54M | $70.80M |
| Current Liabilities | $17.64M | $12.34M | $24.59M | $30.44M | $18.55M | $9.76M |
| Long-term Debt | - | - | - | $0 | - | - |
| Total Liabilities | $167.97M | $160.33M | $188.24M | $168.37M | $9.76M | - |
| Stockholders' Equity | ($66.74M) | ($88.09M) | ($55.99M) | $35.92M | $88.20M | $61.04M |
| Retained Earnings | ($1.06B) | ($1.08B) | ($1.04B) | ($920.98M) | ($721.51M) | ($606.71M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $28.24M | ($37.64M) | ($84.95M) | ($152.37M) | ($84.88M) | ($58.67M) |
| Investing Cash Flow | ($9.0K) | ($30.95M) | ($698.0K) | ($2.34M) | ($9.19M) | ($2.22M) |
| Financing Cash Flow | ($2.79M) | $1.12M | $864.0K | $236.40M | $119.26M | $149.0K |
| CapEx | $9.0K | - | $698.0K | $2.34M | $9.19M | $2.22M |
| Free Cash Flow | $28.23M | - | ($85.65M) | ($154.71M) | ($94.08M) | ($60.89M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | 76.6% | 89.6% | 100.0% | - | - |
| Operating margin | 28.8% | -107.2% | -476.3% | -1929.7% | - | -12722.7% |
| EBITDA margin | 29.0% | -100.7% | -456.5% | -1885.9% | - | -12604.2% |
| Net margin | 26.0% | -118.0% | -505.4% | -1983.6% | - | -12692.4% |
| Free cash flow margin | 37.3% | - | -371.5% | -1538.5% | - | -9884.7% |
| FCF / Net income | 1.44 | - | 0.74 | 0.78 | 0.82 | 0.78 |
| R&D / Revenue | 6.6% | 68.9% | 370.1% | 1166.5% | - | 10111.7% |
| SG&A / Revenue | 46.7% | 115.0% | 195.8% | 166.1% | - | 2711.0% |
| Effective tax rate | 0.0% | - | - | - | - | - |
| Return on assets | 19.4% | -54.6% | -88.1% | -97.6% | -96.0% | -110.4% |
| Return on equity | -29.5% | 44.8% | 208.1% | -555.3% | -130.2% | -128.1% |
| Return on invested capital | - | - | - | -426.8% | - | - |
| Liquidity | ||||||
| Current ratio | 3.82 | 2.95 | 3.96 | 5.95 | 5.07 | 6.91 |
| Quick ratio | 3.46 | 2.47 | 3.87 | 5.88 | 5.07 | 6.91 |
| Cash ratio | 2.65 | 1.72 | 3.57 | 5.67 | 4.90 | 6.74 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.00 | - | - |
| Debt / Assets | - | - | - | 0.00 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -1.52 | -0.82 | -2.36 | 5.69 | 1.36 | 1.16 |
| Liabilities / Assets | 1.66 | 2.22 | 1.42 | 0.82 | 0.08 | - |
| Efficiency | ||||||
| Asset turnover | 0.75 | 0.46 | 0.17 | 0.05 | 0.00 | 0.01 |
| Inventory turnover | - | 1.30 | 1.08 | 0.00 | - | - |
| Days sales outstanding | 42d | 64d | 47d | 50d | - | - |
| Days inventory outstanding | - | 281d | 337d | - | - | - |
| Days payable outstanding | - | 129d | 637d | - | - | - |
| Cash conversion cycle | - | 215d | -253d | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 126.6% | 45.0% | 129.3% | - | -100.0% | - |
| Revenue CAGR (3y) | 96.0% | - | 234.5% | - | - | - |
| Revenue CAGR (5y) | 161.8% | - | - | - | - | - |
| Gross profit growth (YoY) | - | 23.9% | 105.5% | - | - | - |
| Operating income growth (YoY) | - | 67.4% | 43.4% | -68.1% | -47.3% | -86.7% |
| Net income growth (YoY) | - | 66.2% | 41.6% | -73.7% | -46.8% | -86.5% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 44.6% | -64.5% | -54.5% | -30.3% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 24.2% | -57.3% | - | -59.3% | 44.5% | -51.0% |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-7.24
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing LA JOLLA PHARMACEUTICAL CO against the 5 most active filers in the same SIC group.